Our study revealed no significant differences in the hazard of negative control outcomes between the tirzepatide and GLP-1 RA groups for hernia, traumatic intracranial injury, sensorineural hearing loss, lumbar radiculopathy, and skin cancer. The gene discussed is GCG; the disease is skin cancer.